Clinical Trial Update: Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating Magrolimab (Hu5F9-G4) with cetuximab in solid tumors and advanced colorectal cancer completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Solid Tumor

Drugs mentioned

• Cetuximab (cetuximab)
• Magrolimab (magrolimab)

Snippet

Sponsor: Gilead Sciences | Conditions: Solid Tumor, Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-03-01